Hepatitis A virus seroprevalence by age and world region, 1990 and 2005

Vaccine

Volumn 28, Issue 41, 2010, Pages 6653-6657

  Jacobsen, Kathryn H ^a   Wiersma, Steven T ^b  

^a GEORGE MASON UNIVERSITY   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Age distribution; Epidemiology; Hepatitis A; Hepatitis A vaccines; Immunization programs; Meta analysis; Prevalence; Prevention and control; Seroepidemiologic studies

Indexed keywords

HEPATITIS A VACCINE; IMMUNOGLOBULIN G;

ARTICLE; ASIA; AUSTRALIA; CANADA; DISEASE PREDISPOSITION; EASTERN EUROPE; ENDEMIC DISEASE; GEOGRAPHIC DISTRIBUTION; HEPATITIS A; HEPATITIS A VIRUS; HIGH RISK POPULATION; HUMAN; IMMUNITY; IMMUNIZATION; INFECTION CONTROL; JAPAN; LOWEST INCOME GROUP; MIDDLE EAST; NEW ZEALAND; PRIORITY JOURNAL; SEROPREVALENCE; SINGAPORE; SOUTH AND CENTRAL AMERICA; SOUTH KOREA; SYSTEMATIC REVIEW; UNITED STATES; WESTERN EUROPE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VIRUS; HUMANS; INFANT; MIDDLE AGED; SEROEPIDEMIOLOGIC STUDIES; WORLD HEALTH; YOUNG ADULT;

EID: 77956484939     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.037     Document Type: Article

References (21)

1. Wasley A., Fiore A., Bell B.P. Hepatitis A in the era of vaccination. Epidemiol Rev 2006, 28:101-111. doi:10.1093/epirev/mxj012 PMID:16775039.
2. Jacobsen K.H., Koopman J.S. The effects of socioeconomic development on worldwide hepatitis A virus seroprevalence patterns. Int J Epidemiol 2005, 34:600-609. doi:10.1093/ije/dyi062 PMID:15831565.
3. Jacobsen K.H., Koopman J.S. Declining hepatitis A seroprevalence: a global review and analysis. Epidemiol Infect 2004, 132:1005-1022. doi:10.1017/S0950268804002857 PMID:15635957.
4. Hepatitis A vaccines: WHO position paper. Wkly Epidemiol Rec 2000, 75:38-44. PMID:10693358.
5. FitzSimons D., Hendrickx G., Vorsters A., Van Damme P. Hepatitis A and E: update on prevention and epidemiology. Vaccine 2010, 28:583-588. doi:10.1016/j.vaccine.2009.10.136 PMID:9925903.
6. Hendrickx G., Van Herck K., Vorsters A., Wiersma S., Shapiro C., Andrus J.K., et al. Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology. J Viral Hepat 2008, 15(Suppl. 2):1-15. doi:10.1111/j.1365-2893.2008.01022.x PMID:18837827.
7. Cuthbert J.A. Hepatitis A: old and new. Clin Microbiol Rev 2001, 14:38-58. doi:10.1128/CMR. 14. 1. 38-58. 2001 PMID:11148002.
8. Ciocca M. Clinical course and consequences of hepatitis A infection. Vaccine 2000, 18(Suppl. 1):S71-S74. doi:10.1016/S0264-410X(99)00470-3 PMID:10683554.
9. Luyten J., Beutels P. Costing infectious disease outbreaks for economic evaluation: a review for hepatitis A. Pharmacoeconomics 2009, 27:379-389. doi:10.2165/00019053-200927050-00003 PMID:19586076.
10. World Health Organization Hepatitis A vaccines. Wkly Epidemiol Rec 2000, 75:38-44. PMID:10693358.
11. GBD 2005 Study. Global burden of diseases, injuries and risk factors study operations manual (final draft, January 2009). Available from http://www.globalburden.org/.
12. Jacobsen K.H. The global prevalence of hepatitis A virus infection and susceptibility: a systematic review February 2010, World Health Organization, Geneva, [WHO/IVB/10.01].
13. Fischer G.E., Thompson N., Chaves S.S., Bower W., Goldstein S., Armstrong G., et al. The epidemiology of hepatitis A virus infections in four Pacific Island nations, 1995-2008. Trans R Soc Trop Med Hyg 2009, 103:906-910. doi:10.1016/j.trstmh.2009.05.001 PMID:19520409.
14. Sathar M.A., Soni P.N., Fernandes-Costa F.J.T.D., Wittenberg D.F., Simjee A.E. Racial differences in the seroprevalence of hepatitis A virus infection in Natal/Kwazulu, South Africa. J Med Virol 1994, 44:9-12. doi:10.1002/jmv. 1890440104 PMID:7798891.
15. Vitral C.L., Gaspar A.M.C., Souto F.J.D. Epidemiological pattern and mortality rates for hepatitis A in Brazil, 1980-2002: a review. Mem Inst Oswaldo Cruz 2006, 101:119-127. doi:10.1590/S0074-02762006000200001 PMID:16830702.
16. Zhuang G.H., Pan X.J., Wang X.L. A cost-effectiveness analysis of universal childhood hepatitis A vaccination in China. Vaccine 2008, 26:4608-4616. doi:10.1016/j.vaccine.2008.05.086 PMID:18597903.
17. Ansaldi F., Bruzzone B., Rota M.C., Bella A., Ciofi degli Atti M., Durando P., et al. Hepatitis A incidence and hospital-based seroprevalence in Italy: a nation-wide study. Eur J Epidemiol 2008, 23:45-53. doi:10.1007/s10654-007-9198-y PMID:17978852.
18. Al-Faleh F.Z. Changing pattern of hepatitis viral infection in Saudi Arabia in the last two decades. Ann Saudi Med 2003, 23:367-371. PMID:16868370.
19. Ceyhan M., Yildirim I., Kurt N., Uysal G., Dikici B., Ecevit C., et al. Differences in hepatitis A seroprevalence among geographical regions in Turkey: a need for regional vaccination recommendations. J Viral Hepat 2008, 15(Suppl. 2):69-72. doi:10.1111/j.1365-2893.2008.01034.x PMID:18837839.
20. Vacchino M.N. Incidence of hepatitis A in Argentina after vaccination. J Viral Hepat 2008, 15(Suppl. 2):47-50. doi:10.1111/j.1365-2893.2008.01029.x PMID:18837834.
21. Anonychuk A.M., Tricco A.C., Bauch C.T., Pham B., Gilca V., Duval B., et al. Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies. Pharmacoeconomics 2008, 26:17-32. doi:10.2165/00019053-200826010-00003 PMID:18088156.